European journal of nuclear medicine and molecular imaging · 2026
Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolization.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Steinhelfer Lisa, Jungmann Friederike, Endroes Lukas, Nickel Manuel, Schweizer Noemi, Ehmer Ursula, Haller Bernhard, Walter Robert, Spaeth Christopher, Einwächter Henrik, Bodden Jannis, Knorr Karina, Eiber Matthias, Braren Rickmer
Аннотация
PURPOSE: Transarterial radioembolization (TARE) is a well-established treatment for unresectable hepatocellular carcinoma (HCC), though its effects on non-tumorous tissue remain a concern. In particular, the prognostic relevance of splenic volume changes after TARE is not fully understood. This study aimed to assess imaging-derived markers-specifically splenic volume dynamics-as predictors of disease progression.
METHODS: We retrospectively analyzed laboratory and imaging data from 73 patients with histologically or imaging-confirmed HCC who underwent TARE with Yttrium-90 (90Y) at our institution between January 2012 and September 2022. Inclusion criteria were age ≥ 18 years, availability of baseline and 3-month follow-up imaging, and complete clinical documentation. Patients undergoing liver resection, transplantation, or additional therapies during follow-up were excluded.
RESULTS: A relative increase in splenic volume at 3 months was the only independent predictor of progression-free survival (PFS), yielding a ROC-AUC of 0.86 (95%-CI: 0.76-0.95). An increase of 18% or more most accurately identified patients with early disease progression (< 12 months) with a sensitivity 0.74 and specificity 0.97, outperforming conventional clinical and laboratory parameters, including two-dimensional craniocaudal spleen measurements.
CONCLUSIONS: Automated splenic volumetry showed superior prognostic value over traditional markers in HCC patients treated with TARE. A post-treatment increase in spleen volume represents an additional, robust, and readily accessible imaging biomarker for early risk stratification and individualized treatment planning.
METHODS: We retrospectively analyzed laboratory and imaging data from 73 patients with histologically or imaging-confirmed HCC who underwent TARE with Yttrium-90 (90Y) at our institution between January 2012 and September 2022. Inclusion criteria were age ≥ 18 years, availability of baseline and 3-month follow-up imaging, and complete clinical documentation. Patients undergoing liver resection, transplantation, or additional therapies during follow-up were excluded.
RESULTS: A relative increase in splenic volume at 3 months was the only independent predictor of progression-free survival (PFS), yielding a ROC-AUC of 0.86 (95%-CI: 0.76-0.95). An increase of 18% or more most accurately identified patients with early disease progression (< 12 months) with a sensitivity 0.74 and specificity 0.97, outperforming conventional clinical and laboratory parameters, including two-dimensional craniocaudal spleen measurements.
CONCLUSIONS: Automated splenic volumetry showed superior prognostic value over traditional markers in HCC patients treated with TARE. A post-treatment increase in spleen volume represents an additional, robust, and readily accessible imaging biomarker for early risk stratification and individualized treatment planning.